Since many previous studies have shown that KEAP1/NFE2L2 mutation is associated with poor prognosis of NSCLC, it is of great clinical significance to determine which treatment method can improve the prognosis of NFE2L2/KEAP1 mutant population. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.